All web articles
—New intellectual property ‘think tank’ draft policy already showing alarming trend—
MSF response to GSK and Pfizer’s statement on the pneumonia vaccine (pneumococcal conjugate vaccine, PCV)
“We disagree that US$5 for three doses of the pneumococcal vaccine is unsustainable, especially considering that GSK and Pfizer have together made more than $19 billion on the PCV vaccine to date....
MSF calls on GSK and Pfizer to slash pneumo vaccine price to $5 per child for poor countries ahead of donor meeting
In July 2014, MSF held the first of three rounds of a mass vaccination campaign in Adjumani district of northern Uganda to protect children from deadly respiratory infections. © Sydelle WIllow Smith
MSF is grateful for donations of the pneumococcal conjugate vaccine (PCV) that help us protect vulnerable children against pneumonia in some of our operations. However, donations are not MSF's preferred...
Last updated 19 January 2015
© Siddharth Singh
Last updated 14 January 2015
A clinical trial of a possible treatment for Ebola began on the 1st of January at ELWA 3, MSF’s Ebola Management Centre in Monrovia.
Last updated 7 January 2015
For over a year, the European Union (EU) has been negotiating a review of its trademark legislation and drawing up new provisions to include in the law. The draft law features a new right to enforce...
Last updated 18 December 2014
On 12 December the Indian Supreme Court rejected Bayer’s appeal to block production and sales of a lower-cost version of its exorbitantly expensive cancer medication, sorafenib tosylate (marketed as...
Last updated 15 December 2014
Médecins Sans Frontières responds to the news of the donation: “Janssen’s new TB drug bedaquiline has been on the market for two years, yet to date around only 500 people have been treated with...
Last updated 12 December 2014
BRICS countries must boost investments in research to defeat deadly drug-resistant tuberculosis crisis
Political will remains key barrier to deploying BRICS resources towards the development of a new generation of treatments for drug-resistant TB
Last updated 5 December 2014